Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ViiV’s Visibility Grows And Pressure Mounts For What Comes Next

04 Apr 2016

• By Jessica Merrill

Related Content

Tivicay Launch Returns ViiV To HIV Spotlight And Growth

19 Aug 2013

Glaxo and Pfizer Form HIV Venture, But A Spin-Off Could Be In The Wings

20 Apr 2009

ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value

06 May 2015

Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future

17 Mar 2016

Keeping Track: Imbruvica Snags First-Line CLL Claim; Gilead TAF Strategy Advances

07 Mar 2016

Related Companies

GSK plc

ViiV Healthcare

Pfizer Inc.

Shionogi & Co. Ltd.

Gilead Sciences, Inc.

Novartis AG

Johnson & Johnson

Bristol Myers Squibb Company

Additional Topics

Business Strategies Strategy Launches BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.